G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Elihu H. Estey,Guillermo Garcia-Manero,Alessandra Ferrajoli,Stefan Faderl,Srdan Verstovsek,Dan Jones,Hagop M. Kantarjian +6 more
TL;DR: ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL and, when combined with GO, may improve outcome in high-risk patients.
Journal ArticleDOI
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi,Mona Lisa Alattar,Michael R. Grunwald,Michelle A. Rudek,Trivikram Rajkhowa,Mary Ann Richie,Sherry Pierce,Naval Daver,Guillermo Garcia-Manero,Stefan Faderl,Aziz Nazha,Marina Konopleva,Gautam Borthakur,Jan A. Burger,Tapan M. Kadia,Sara Dellasala,Michael Andreeff,Jorge E. Cortes,Hagop M. Kantarjian,Mark J. Levis +19 more
TL;DR: The combination of AZA and sorafenib is effective for patients with relapsed AML and FLT-3-ITD and sixty-four percent of patients achieved adequate FLT3 inhibition during their first cycle of therapy.
Journal ArticleDOI
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi,Jorge E. Cortes,Dan Jones,Stefan Faderl,Guillermo Garcia-Manero,Marina Konopleva,Susan O'Brien,Zeev Estrov,Gautam Borthakur,Deborah A. Thomas,Sherry Pierce,Mark Brandt,Anna Byrd,B. Nebiyou Bekele,Keith W. Pratz,Rajyalakshmi Luthra,Mark J. Levis,Michael Andreeff,Hagop M. Kantarjian +18 more
TL;DR: Sorafenib can be safely combined with chemotherapy, produces a high CR rate in FLT3-mutated patients, and inhibitsFLT3 signaling.
Journal ArticleDOI
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point
Rachel Darman,Michael Seiler,Anant A. Agrawal,Kian Huat Lim,Shouyong Peng,Daniel Aird,Suzanna L. Bailey,Erica B. Bhavsar,Betty Chan,Simona Colla,Laura Corson,Jacob Feala,Peter Fekkes,Kana Ichikawa,Keaney Gregg F,Linda Lee,Pavan Kumar,Kaiko Kunii,Crystal MacKenzie,Mark Matijevic,Yoshiharu Mizui,Khin Than Myint,Eun Sun Park,Xiaoling Puyang,Anand Selvaraj,Michael P. Thomas,Jennifer Tsai,John Wang,Markus Warmuth,Hui Yang,Ping Zhu,Guillermo Garcia-Manero,Richard R. Furman,Lihua Yu,Pete Smith,Silvia Buonamici +35 more
TL;DR: It is reported that common and tumor-specific splicing aberrations are induced by SF3B1 mutations and establish aberrant 3' ss selection as the most frequent splicing defect.
Journal ArticleDOI
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Farhad Ravandi,Eli Estey,Dan Jones,Stefan Faderl,Susan O'Brien,Jackie Fiorentino,Sherry Pierce,Deborah Blamble,Zeev Estrov,William G. Wierda,Alessandra Ferrajoli,Srdan Verstovsek,Guillermo Garcia-Manero,Jorge E. Cortes,Hagop M. Kantarjian +14 more
TL;DR: The combination of ATRA and ATO (with or without GO) as initial therapy for APL was effective and safe and can substitute chemotherapy-containing regimens.